All News


 

2017

January

Media Release / Jan 31, 2017

Sandoz Canada launches Sandoz® Amphetamine XR for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Read More
2016

July

Media Release / Jul 07, 2016

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Read More

June

Media Release / Jun 28, 2016

Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada

Read More
Media Release / Jun 21, 2016

Sandoz Canada Launches First Non-Prescription Naloxone Approved by Health Canada for Treating Opioid Overdoses

Read More
Media Release / Jun 13, 2016

Sandoz Canada concludes a new collective agreement with unionized employees at its Boucherville plant

Read More
Media Release / Jun 09, 2016

New data demonstrates sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

Read More
Media Release / Jun 07, 2016

Sandoz Canada is committed to maintain a supply of injectable medicines during work stoppage by unionized employees at its Boucherville facility

Read More

May

Media Release / May 31, 2016

Sandoz broadens its pharmaceutical portfolio with EURO-PHARM's North American product line

Read More
Media Release / May 17, 2016

Sandoz Canada launches PrSandoz® Duloxetine, a generic version of Cymbalta*, for the treatment of depression and anxiety symptoms

Read More

March

Media Release / Mar 31, 2016

Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI* indicated for pulmonary infections in cystic fibrosis patients

Read More